Table 1 Clinical characteristics and medication use among the women with RA
From: Is gene expression among women with rheumatoid arthritis dysregulated during a postpartum flare?
Patient | RA duration* (years) | RF | ACPA | Medication use | ||
|---|---|---|---|---|---|---|
3rd trimester (T3) | 3 months postpartum (PP3) | 6 months postpartum (PP6) | ||||
RAFlare | ||||||
1 | 10.3 | + | + | PRDL + SSZ | PRDL | PRDL + corticosteroid (Diprospan) |
2 | 4.7 | + | + | PRDL + SSZ | – | PRDL + MTX |
3 | 9.4 | – | + | PRDL + SSZ | PRDL + SSZ | PRDL + glucocorticoid |
4 | 2.6 | NA | NA | – | PRDL + SSZ + HCQ | SSZ + HCQ + MTX |
5 | 2.1 | NA | + | PRDL | PRDL | PRDL |
6 | 3.8 | + | + | SSZ | PRDL + SSZ + MTX | SSZ + MTX |
7 | 2.1 | – | – | – | – | PRDL |
8 | 5.4 | NA | + | SSZ | PRDL + SSZ | SSZ |
9 | 2.4 | – | + | PRDL + SSZ | PRDL + SSZ | PRDL + MTX |
RANoFlare | ||||||
1 | 9.3 | – | – | – | – | – |
2 | 2.4 | + | + | SSZ | MTX | MTX |
3 | 10.5 | – | – | Corticosteroid (Diprospan) | – | MTX + IFX |